H. M. Morgan

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.

Dean M. Messing, G. Anderson, J. Monahan, 2011, Bioorganic & medicinal chemistry letters.

Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.

David R. Anderson, S. Wright, V. Rao, 2017, Journal of medicinal chemistry.

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.

Dean M. Messing, G. Anderson, J. Monahan, 2011, Bioorganic & medicinal chemistry letters.

Examination of the kinetic mechanism of mitogen-activated protein kinase activated protein kinase-2.

T. Kasten, J. F. Schindler, J. Monahan, 2002, Biochimica et biophysica acta.